NCT00245102View on ClinicalTrials.gov

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Adult AngiosarcomaAdult Epithelioid SarcomaAdult LeiomyosarcomaAdult Malignant Fibrous HistiocytomaAdult NeurofibrosarcomaAdult Synovial SarcomaOvarian SarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Uterine SarcomaStage III Adult Soft Tissue SarcomaStage III Uterine SarcomaStage IV Adult Soft Tissue SarcomaStage IV Uterine SarcomaUterine CarcinosarcomaUterine Leiomyosarcoma
Interventions
DRUG

sorafenib tosylate

Given orally

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00245102 - Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | Biotech Hunter | Biotech Hunter